We report the case of a 38-year-old man admitted to the emergency department with respiratory distress syndrome and lower left limb swelling, further associated to edema at physical examination. Contrast computerized tomography (CT) scan highlighted a small circle of embolism in the left lung, while in abdomen a retroperitoneal mass of 140 × 100 × 180 mm, indissociable from the left psoas, incorporating aorta, carrefour and common iliac arteries, with lateral displacement of renal vein and upper urinary hydronephrosis of the left kidney, was detected. A severe compression of the subhepatic cava and a thrombosis of the right common iliac vein and of the left iliac femoral venous system were also reported. Bilateral ultrasonography of the testis revealed starry sky calcifications with irregular distribution and a 2-cm hypoechoic area in the left testicle. Left orchiectomy was performed, including the entire testicular parenchyma, epididymis and spermatic cord. The histopathologic examination described plurifocal intratubular germinal neoplasia, diffuse atrophy of seminiferous tubules, plurifocal Leydig cell hyperplasia and a fibrotic area with lymphohystiocytic infiltrate, siderophages and stromal calcifications. Epididymis, spermatic cord and resection margins were not affected by the neoplasia. The immunohistochemistry was negative for human chorionic gonadotropin (hCG) β subunit, even in the areas with intratubular neoplasia. Three weeks after starting treatment with low molecular weight heparin, a CT scan-guided biopsy of the retroperitoneal mass was done; the histopathological examination showed a monomorphic population of neoplastic cells with a round nucleus, prominent nucleolus and inconspicuous cytoplasmic membranes. A diagnosis of malignant germ cell tumor (GCT) was made (tumor stage, pT0N1). The immunohistochemistry positivity of octamer-binding transcription factors 3 and 4, focal positivity of CD30 and negativity for α-fetoprotein (AFP), hCGβ and pan cytokeratin cocktail led to hypothesize a seminomatous component in a mixed GCT. The patient received three cycles of chemotherapy with bleomycin, etoposide and cisplatin (BEP). One week after the third cycle, CT showed a partial remission of the retroperitoneal mass (to 48 × 44 × 89 mm) with venous thrombus still present. As positron emission tomography with fluorodeoxyglucose (FDG-PET) underlined a moderate metabolic activity, the patient received two additional cycles of BEP. Two months later, CT scan showed a further slight reduction of the retroperitoneal mass (45 × 35 × 78 mm). However, accounting for the persistence of some metabolic activity at FDG-PET despite the five BEP cycles, a tumor debulking with retroperitoneal lymphectomy was performed. An ovoidal (65 × 40 × 30 mm), diffusely necrotic mass was removed and sent to the pathology laboratory. Histologically, the mass was constituted by a diffuse substitution of lymph nodal parenchyma by fibrous tissue, mixed with necrotic areas and a diffuse lymphohistiocytic infiltrate with a multifocal granulomatous reaction. No residual neoplastic cells were present. Figure 1 displays the laboratory marker profile obtained from diagnosis up to the final resolution of the case (200 days). At admission, serum AFP was undetectable, total hCG (Elecsys 'hCG + β' assay, Roche Diagnostics) was 30 U/L (recommended cut-off for men <50 years, 0.3 U/L) and lactate dehydrogenase (LDH) 898 U/L (upper reference limit [URL], 220 U/L). Five days after orchiectomy,
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To assess if these hCG + β variations in the postchemotherapy period may represent a biochemical sign of residual disease, there is a need to define the impact of the analytical variability of the assay at these low concentrations and to exclude hypogonadism inducing hCG secretion [3] . Lacking analytical performance specifications to apply to the hCG measurement in oncology, it is difficult to objectively define the goodness of the assay imprecision as well as the entity of marker increases that may be a sign of biochemical relapse [4] . In our experience, the Elecsys 'hCG + β' assay performed on the Cobas e801 platform displays an acceptable imprecision for its use in oncology, with a CV of ~10% at hCG + β concentrations around 0.4 U/L. On the other hand, we were able to show that the hCG + β peak at 1.1 U/L in our patient was concomitant to luteinizing hormone and follicle-stimulating hormone concentrations of 29.4 U/L (URL: 8.6) and 32.8 U/L (URL: 12.4), respectively, and total and free testosterone concentrations of 8.3 nmol/L (lower reference limit [LRL]: 8.7) and 14.9 pmol/L (LRL: 28.8), respectively, indicating probable hypogonadism.
An important point relates to the choice of the appropriate assay for measuring hCG in oncology [5] . In our laboratory system, we have two assays in service for measuring hCG, one validated only for the early detection of pregnancy (Abbott Architect Total β-hCG) and included in the core laboratory menu, and the second one (Roche Elecsys hCG + β), cleared even for oncological application, used in the laboratory section specialized in tests for oncology. At admission of the patient, clinicians erroneously ordered the hCG Abbott, so laboratory professionals corrected the request and then recommended the ordering of hCG + β Roche for further evaluation. Nevertheless, we performed internally a head-to-head comparison between hCG results obtained by Abbott and Roche assays on all samples collected in our patient to show the possible impact of using different assays for measuring hCG as a cancer biomarker. Out of 22 hCG determinations carried out in the patient during the hospitalization, we observed 13 Architect results (59%) lower than the assay's analytical sensitivity (1.2 U/L declared by the manufacturer as the concentration at two standard deviations from the mean signal value of the Architect zero calibrator, which is actually the limit of blank and not the LoD) and only three (13.6%) for Elecsys assay (LOD, 0.2 U/L) ( Figure 2) . The regression analysis on the nine results detectable for both assays revealed a statistical significance (p < 0.0001) in the slope of the equation (Roche = 1.16 Abbott − 0.8).
Considering that both assays are calibrated against the 4th WHO international standards hCG 75/589, one may postulate that the difference can be due to the broader selectivity of the Roche assay for hCG forms expressed in cancer [5] and the slower rate of disappearance of free β subunit when compared with intact hCG [6] .
Although rare, there are in literature papers about BTT cases describing the difficult diagnosis and management of this metastatic extragonadal GCT with histological regression of the primary testicular lesion likely due to ischemia caused by neoplasm outgrowing its blood supply [7] [8] [9] . Choriocarcinomas followed by embryonal carcinoma are most likely to burn out, whereas regression is uncommon in seminoma. Different histotypes may characterize mixed BTT and the different neoplastic elements may respond differently to the therapy. Considering that orchiectomy and target chemotherapy may drastically change the prognosis, it is crucial both to early identify and to characterize histologically the malignancy, as the absence of specific symptoms may delay the diagnostic workup. In this scenario, it is recommended to carefully consider the measurement of appropriate tumor markers in serum (AFP, hCG, LDH) both at diagnosis as complementary to immunohistochemistry and during therapeutic monitoring to early detect the residual disease [9] . Considering the results of histopathological inspection and negative immunohistochemistry on the testicular tissue, the marked increase in serum hCG + β at the patient diagnosis suggested a BTT and allowed to hypothesize a seminomatous component within a mixed tumor after the examination of biopsy sample of the retroperitoneal mass. As in our case, contrasting results between serum and immunohistochemical detection of hCG have been reported and may be associated with the possibility to lose/neglect some tumor components during biopsy and/or with the immediate secretion of hCG in the bloodstream as it is generally not stored within secretory granules [10, 11] .
Even the interpretation of marker changes during surveillance after orchiectomy and then after chemotherapy merits attention. Five days after orchiectomy, hCG + β decreased only by 29% when compared with the peak concentration. Considering an average marker half-life of 3.5 days [4] , the slow decrease was suggestive of a residual source of hCG from the retroperitoneal mass. After initial chemotherapy, the presence of massive necrotic tissue may provide false-positive results at imaging [12] : in our case, the final exhaustive histological examination of sections from retroperitoneal mass debulking supported this hypothesis. On the other hand, interpreting hCG during chemotherapy monitoring is difficult as there are no reference data in literature. For instance, the increase to 1.1 U/L after reaching undetectable hCG + β concentrations in serum after the first BEP cycle could be at first suggestive of a residual disease. However, the fluctuating behavior of hCG concentrations finally suggested the pituitary origin of the marker due to possible hypogonadism, a hypothesis which may be supported by sex hormone measurements and by authoritative data [3] . Finally, this case is a clear evidence of how the management of hCG + β results may impact the outcome and the quality of life of the patient. Undoubtedly, in our case, hCG + β allowed the early diagnosis of a complex testicular tumor with poor prognosis and may be considered the most sensitive tool for the early recognition of the relapse. On the other hand, during surveillance, hCG + β monitoring with exclusion of possible spurious increases avoids unnecessary further overtreatment and correlated side effects when imaging is not suggestive.
We submitted the case report as an observational study to the Institutional Review Board (IRB), but the board stated that this study does not require ethical approval. Informed consent was obtained from the patient.
